HDA, in collaboration with Vantage Solutions, conducted a series of quarterly surveys in 2022 to assess the healthcare supply chain’s progress toward implementing GS1 Electronic Product Code Information Services (EPCIS), as well as trading partner plans for exchanging data, to comply with the Drug Supply Chain Security Act (DSCSA). The Q4 2022 summary is the last survey in the series.

The DSCSA requires transaction data with product identifiers to be provided with physical product on November 27, 2023.The FDA has recommended that trading partners use the EPCIS standard to provide and maintain the data associated with transaction information and transaction statements. This survey informs industry trading partners on the status of successful data connections, defined as “a connection that is fully integrated and working in a production environment,” and perceived obstacles to implementation. Data reflect responses from manufacturers and distributors.

This executive summary is a follow-up to the HDA EPCIS Implementation Benchmarking Survey conducted in October 2022.